Clarivate Epidemiology’s coverage of cutaneous lupus erythematosus (CLE) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed…
DRG Epidemiology's coverage of venous thromboembolism prophylaxis in cancer comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the…
Clarivate Epidemiology’s coverage of SLE comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of SLE for each country, as well as…
DRG Epidemiology’s coverage of systemic lupus erythematosus (SLE) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…
DRG Epidemiology’s coverage of systemic lupus erythematosus (SLE) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…
DRG Epidemiology’s coverage of systemic lupus erythematosus (SLE) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…
Clarivate Epidemiology’s coverage of systemic lupus erythematosus (SLE) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…
DRG Epidemiology’s coverage of systemic lupus erythematosus (SLE) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…
Characterized by high incidence and long treatment durations, the breast cancer therapy market represents substantial commercial opportunity for drug developers. CDK4/6 inhibitors (Pfizer’s…
The treatment landscape for COVID-19 continues to evolve rapidly. Even with vaccines having become available in the markets under study, intense ongoing research has also focused on approaches…
Clarivate Epidemiology's coverage of BRAF comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany,…
The number of diagnosed prevalent cases of SCA in the countries under study will increase by 10% over the 20-year forecast period, from 29,000 to 32,000. Of the countries considered in this…
Clarivate Epidemiology's coverage of non-alcoholic steatohepatitis (NASH) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the…
Clarivate Epidemiology’s coverage of nonalcoholic steatohepatitis (NASH) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…
DRG Epidemiology's coverage of non-alcoholic fatty liver disease (NAFLD) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence…
